Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Oncaspar

Bristol-Myers Squibb (BMS) building

BMS gets OK for monthly Opdivo dosing

Analysts predict the new dosing schedule could see the pharma giant win market share

Gilead Sciences

Gilead says switching studies back new HIV therapy Biktarvy

Patients who switched from rival Triumeq could maintain viral suppression over the trial period

Gilead Sciences

Gilead study resurrects HIV eradication hope

Intends to start human trials of its improved bNAb candidate

AstraZeneca AZ

CHMP backs AZ’s Lynparza for ovarian cancer maintenance

Studies show that the drug reduced risk of disease progression

Gilead Sciences

Gilead signs $3bn-plus gene-editing deal with Sangamo

Will use the platform for new cell-based cancer therapies

- PMLiVE

AZ adds another Ionis drug in $330m kidney disease deal

The candidate targets a genetically associated form of the condition

- PMLiVE

Merck/Pfizer’s cancer immunotherapy latecomer hits a snag

Bavencio fails a key lung cancer trial

Bristol-Myers Squibb (BMS) building

BMS pens massive $3.6bn deal for Nektar cancer immunotherapy

Nektar’s NKTR-214 to be paired with Opdivo and Yervoy in a host of tumour types

- PMLiVE

Gilead’s triple HIV drug approval prompts GSK lawsuit

ViiV claims bictegravir infringes its patent estate

Bristol-Myers Squibb (BMS) building

BMS’ Opdivo plus Yervoy aces phase III trial

The cancer drug combo met one of its primary endpoints in NSCLC patients

- PMLiVE

AZ expects return to growth this year after 2017 decline

Soriot says the pharma company is 'turning a corner'

The ‘Million Hour Challenge’

AstraZeneca employees save two million hours through simplification

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links